In propensity-matched adults with type 2 diabetes and peripheral artery disease or foot ulcers, injective or oral semaglutide was linked to fewer major limb events than other glucose-lowering therapies (HR 0.77).
In plain wordsIn adults with type 2 diabetes and artery disease or foot ulcers, semaglutide use was linked to fewer major limb events than other diabetes drugs.
- Peptide
- Semaglutide
- Outcome
- DecreaseMajor limb events (composite of PTA or critical limb ischaemia)
- Study
n = 334
- Comparator
- Other glucose-lowering therapies
- Analysis
- Primary
- Outcome group
- Cardiovascular events · Cardiovascular
- Studied dose
- Dose not stated
Measurements
- Hazard ratio
- 0.77 HR
- semaglutide vs other glucose-lowering therapies
Source sentences
During a median follow-up of 30.1 months, a primary-outcome event occurred in 72 of the participants (43.0%; incidence, 8.1 events per 100 person-years) in the semaglutide group, as compared with 93 of the participants (56.0%; incidence, 10.4 events per 100 person-years) in the GLT group (hazard rat…
2 context sentences(design, population, supporting numbers)
Participants had to have type 2 diabetes and a diagnosis of peripheral artery disease (PAD) or foot ulcers.
We analysed two matched groups of 167 participants each, who were predominantly males (57%), aged 61 years, with a 12-year duration of diabetes, a baseline HbA1c of 8.0% and body mass index (BMI) of 31 kg/m2.